Compare VNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNT | BLCO |
|---|---|---|
| Founded | 2019 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | VNT | BLCO |
|---|---|---|
| Price | $37.71 | $17.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 14 |
| Target Price | ★ $46.11 | $17.31 |
| AVG Volume (30 Days) | ★ 1.2M | 341.8K |
| Earning Date | 02-12-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | $3,043,900,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $2.79 | $8.06 |
| Revenue Next Year | $3.10 | $5.79 |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | 1.76 | ★ 6.23 |
| 52 Week Low | $27.22 | $10.45 |
| 52 Week High | $43.88 | $18.55 |
| Indicator | VNT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 58.60 |
| Support Level | $37.58 | $16.76 |
| Resistance Level | $38.27 | $17.23 |
| Average True Range (ATR) | 0.58 | 0.32 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 76.14 | 63.68 |
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.